The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CABA | -9.48% | -84.21% | -30.84% | -78% |
| S&P | +16.95% | +80.97% | +12.59% | +129% |
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$345.00K | 18.6% |
| Market Cap | $214.03M | -7.2% |
| Market Cap / Employee | $1.45M | 0.0% |
| Employees | 148 | 0.0% |
| Net Income | -$44,866.00K | -46.5% |
| EBITDA | -$46,243.00K | -41.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $60.21M | -64.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.56M | -37.5% |
| Short Term Debt | $21.22M | 167.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -80.43% | -25.3% |
| Return On Invested Capital | -44.16% | -12.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34,587.00K | -68.1% |
| Operating Free Cash Flow | -$34,509.00K | -69.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.64 | 0.46 | 0.63 | 1.20 | 4.95% |
| Price to Tangible Book Value | 0.64 | 0.46 | 0.63 | 1.20 | 4.95% |
| Enterprise Value to EBITDA | 1.03 | 0.89 | 1.67 | -2.27 | 12.87% |
| Return on Equity | -59.6% | -73.9% | -76.3% | -101.1% | 62.60% |
| Total Debt | $15.60M | $28.79M | $24.89M | $25.78M | 69.34% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
